Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1923 1
1951 1
1952 3
1953 1
1963 2
1967 1
1972 2
1973 3
1974 4
1975 31
1976 60
1977 45
1978 53
1979 77
1980 58
1981 77
1982 85
1983 127
1984 119
1985 159
1986 158
1987 196
1988 192
1989 281
1990 339
1991 322
1992 416
1993 448
1994 503
1995 537
1996 625
1997 587
1998 640
1999 620
2000 681
2001 722
2002 772
2003 818
2004 833
2005 946
2006 950
2007 973
2008 1081
2009 1098
2010 1231
2011 1380
2012 1540
2013 1735
2014 1869
2015 2081
2016 2174
2017 2274
2018 2287
2019 2590
2020 2931
2021 584
Text availability
Article attribute
Article type
Publication date

Search Results

34,646 results
Results by year
Filters applied: . Clear all
Page 1
Genetic and epigenetic determinants of AML pathogenesis.
Cai SF, Levine RL. Cai SF, et al. Semin Hematol. 2019 Apr;56(2):84-89. doi: 10.1053/j.seminhematol.2018.08.001. Epub 2018 Aug 22. Semin Hematol. 2019. PMID: 30926095 Review.
Acute myeloid leukemia (AML) was one of the first cancers to be sequenced at the level of the whole genome. Molecular profiling of AML through targeted sequencing panels and cytogenetics has become a mainstay in risk-stratifying AML patients and guiding clini …
Acute myeloid leukemia (AML) was one of the first cancers to be sequenced at the level of the whole genome. Molecular profiling of …
Targeted Therapies for Pediatric AML: Gaps and Perspective.
Lonetti A, Pession A, Masetti R. Lonetti A, et al. Front Pediatr. 2019 Nov 15;7:463. doi: 10.3389/fped.2019.00463. eCollection 2019. Front Pediatr. 2019. PMID: 31803695 Free PMC article. Review.
However, childhood AML prognosis remains unfavorable and relapse rates are still around 30%. ...This review will discuss several new drugs that recently received US Food and Drug Administration approval for AML treatment and promising strategies to treat childhood …
However, childhood AML prognosis remains unfavorable and relapse rates are still around 30%. ...This review will discuss several new …
CPX-351 (vyxeos) in AML.
Alfayez M, Kantarjian H, Kadia T, Ravandi-Kashani F, Daver N. Alfayez M, et al. Leuk Lymphoma. 2020 Feb;61(2):288-297. doi: 10.1080/10428194.2019.1660970. Epub 2019 Sep 24. Leuk Lymphoma. 2020. PMID: 31547736
In August 2017 the US FDA approved CPX-351 (vyxeos), a liposomal formulation of cytarabine and daunorubicin at a fixed 5:1 molar ratio, for the treatment of adults with newly diagnosed AML with myelodysplasia-related changes (AML-MRC) and therapy-related AML
In August 2017 the US FDA approved CPX-351 (vyxeos), a liposomal formulation of cytarabine and daunorubicin at a fixed 5:1 molar ratio, for …
AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances.
Koenig KL, Sahasrabudhe KD, Sigmund AM, Bhatnagar B. Koenig KL, et al. Genes (Basel). 2020 Jul 24;11(8):845. doi: 10.3390/genes11080845. Genes (Basel). 2020. PMID: 32722092 Free PMC article. Review.
Acute myeloid leukemia (AML) with myelodysplasia-related changes (AML-MRC) is a distinct biologic subtype of AML that represents 25-34% of all AML diagnoses and associates with especially inferior outcomes compared to non-MRC AML. ...In light of …
Acute myeloid leukemia (AML) with myelodysplasia-related changes (AML-MRC) is a distinct biologic subtype of AML that r …
Is there a standard of care for relapsed AML?
Medeiros BC. Medeiros BC. Best Pract Res Clin Haematol. 2018 Dec;31(4):384-386. doi: 10.1016/j.beha.2018.09.006. Epub 2018 Sep 20. Best Pract Res Clin Haematol. 2018. PMID: 30466752 Review.
Despite advances in treatment for acute myeloid leukemia (AML), the prognosis for patients with relapsed disease is extremely poor. ...A brief review follows on the progress made in establishing a standard of care for relapsed AML....
Despite advances in treatment for acute myeloid leukemia (AML), the prognosis for patients with relapsed disease is extremely poor. . …
The cytokine network in acute myeloid leukemia (AML): A focus on pro- and anti-inflammatory mediators.
Binder S, Luciano M, Horejs-Hoeck J. Binder S, et al. Cytokine Growth Factor Rev. 2018 Oct;43:8-15. doi: 10.1016/j.cytogfr.2018.08.004. Epub 2018 Aug 29. Cytokine Growth Factor Rev. 2018. PMID: 30181021 Review.
While pro-inflammatory mediators such as IL-1beta, TNF-alpha and IL-6 tend to increase AML aggressiveness, anti-inflammatory mediators such as TGF-beta and IL-10 appear to impede AML progression. ...This article summarizes current knowledge about the functions of pr …
While pro-inflammatory mediators such as IL-1beta, TNF-alpha and IL-6 tend to increase AML aggressiveness, anti-inflammatory mediator …
Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC).
Arber DA, Erba HP. Arber DA, et al. Am J Clin Pathol. 2020 Nov 4;154(6):731-741. doi: 10.1093/ajcp/aqaa107. Am J Clin Pathol. 2020. PMID: 32864703 Free PMC article. Review.
OBJECTIVES: Acute myeloid leukemia (AML) with myelodysplasia-related changes (AML-MRC) represents a high-risk and somewhat diverse subtype of AML, and substantial confusion exists about the pathologic evaluation needed for diagnosis, which can include the pat …
OBJECTIVES: Acute myeloid leukemia (AML) with myelodysplasia-related changes (AML-MRC) represents a high-risk and somewhat div …
MicroRNA-155 expression and function in AML: An evolving paradigm.
Narayan N, Bracken CP, Ekert PG. Narayan N, et al. Exp Hematol. 2018 Jun;62:1-6. doi: 10.1016/j.exphem.2018.03.007. Epub 2018 Mar 27. Exp Hematol. 2018. PMID: 29601851 Review.
Acute leukemia is the most common form of pediatric cancer, with AML accounting for ~20% of all leukemias in children. The genomic aberrations that drive AML inhibit myeloid differentiation and activate signal transduction pathways that drive proliferation. ...Under …
Acute leukemia is the most common form of pediatric cancer, with AML accounting for ~20% of all leukemias in children. The genomic ab …
Targeting CXCR4 in AML and ALL.
Cancilla D, Rettig MP, DiPersio JF. Cancilla D, et al. Front Oncol. 2020 Sep 4;10:1672. doi: 10.3389/fonc.2020.01672. eCollection 2020. Front Oncol. 2020. PMID: 33014834 Free PMC article. Review.
The interaction of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) blasts with the bone marrow microenvironment regulates self-renewal, growth signaling, as well as chemotherapy resistance. ...In this review we will discuss recent results and strategies …
The interaction of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) blasts with the bone marrow microenvironment r …
Autologous Transplantation for Older Adults with AML.
Mueller BU, Seipel K, Bacher U, Pabst T. Mueller BU, et al. Cancers (Basel). 2018 Sep 19;10(9):340. doi: 10.3390/cancers10090340. Cancers (Basel). 2018. PMID: 30235847 Free PMC article. Review.
While the majority of patients with acute myeloid leukemia (AML) are above the age of 65 years at diagnosis, the outcome of older AML patients remains disappointing. ...Consequently, clinicians face the dilemma that there is considerable ambiguity on the most approp …
While the majority of patients with acute myeloid leukemia (AML) are above the age of 65 years at diagnosis, the outcome of older …
34,646 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page